If other officers were selling than I'd have to think about it. I'm not concerned here. The recent news can't be denied. Everything is going great. I don't see any reason why we won't see an early approval even just for humanitarian reasons. These people are dying and CLDX is there last hope.
The guy is retiring. We've been through this before. Not worth even mentioning. Unless your a short as we know some are on this board and have been watching the share price start to climb on recent good news.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) added 0.56% and closed at $17.89 in the last trading session. The last trading range of the stock ranges between $17.69 and $18.24. The Earnings per Share of the company stands at $-1.33. The 52 Week Range shows that the stock reached Higher at $32.82 while its Lower range is $10.11 in the last 52 weeks. The Average Volume of the company is at 2.46 Million with the Outstanding Shares of 98.65 Million. The market capitalization of the company is $1.76 billion. The Beta of the company stands at 3.21 with the RSI (Relative Strength Index) of 73.49.
Why do you assume its going to pull back? And if it doesn't you will buy at a higher price? I think cldx has pulled back enough. it dropped to 10.11. Now with the most recent news its on an upward move. if you buy, take a half of position and then if it does drop cost average. It worked well for me.
11/13/2015 18,893,930 2,007,546 9.411456
10/30/2015 18,287,148 2,463,139 7.424326
I like that. Share price has moved higher without the shorts covering. Wait till panic sets in.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) declined -1.77% to end last trading session at $17.79. The company, on Nov. 6, 2015, presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Results suggest that cancers may respond to CD27 immune modulation by independent mechanisms, such as immune co-stimulation and regulatory T cell (Treg) depletion. Varlilumab has the unique ability to act through both of these mechanisms. The new data were presented in a poster entitled “The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent” at the Society for the Immunotherapy of Cancer (SITC) Annual Meeting.
That's because in your best interest you don't want it. At least be honest about it.
CLDX is still trading at just above 1x sales. That is significantly below the average for the biotech sector. The average for the biotech industry is around 10x sales, according to data from Stern. Even assigning a conservative multiple of 5x sales to CLDX, gives a price per share of $75. ***********75************** sounds reasonable to me.
On Monday, Celldex Therapeutics (NASDAQ:CLDX) shares rose nearly 12%, extending their gains from Friday. CLDX has gained almost 25% since Friday. The gains have come after the company presented mature survival data from its Phase 2 ReACT study of RINTEGA in patients with EGFRvIII-positive, recurrent glioblastoma (OTCPK:RGBM). The data once again highlighted the potential of RINTEGA. Celldex's shares though still do not reflect the potential of the brain cancer vaccine notwithstanding the gains made in the last two days.
Despite the rally in the last two days, CLDX shares are still down more than 13% in the last one year. The stock has come under selling pressure since mid-July. Last year, CLDX fell more than 20% even though the company continued to advance the RINTEGA and glembatumumab programs. One reason why CLDX has struggled this year is because of the lack of catalysts, as noted by Seeking Alpha author Brian Nichols in an article in August. The negative sentiment on the biotech sector has also played its part. Amid of all of this though, CLDX has continued to advance RINTEGA and glembatumumab. And now with several catalysts coming in 2016, including interim analysis from the ACT IV study, CLDX could see further upside in the next few months.
At current levels, CLDX still offers an attractive entry point. As I had discussed in an article earlier this year, the combined risk adjusted peak sales estimate for RINTEGA and glembatumumab comes to around $1.5 billion. Based on this estimate, CLDX is still trading at just above 1x sales. That is significantly below the average for the biotech sector. The average for the biotech industry is around 10x sales, according to data from Stern. Even assigning a conservative multiple of 5x sales to CLDX, gives a price per share of $75.
Celldex Therapeutics, Inc. (CLDX - Analyst Report) was a big mover last session, as the company saw its shares rise nearly 12% on the day. The share price appreciation came after the company presented mature survival data from a phase II study on Rintega at the annual meeting of the Society for Neuro-Oncology. The news led to far more shares changing hands than in a normal session, breaking the recent trend for the company as the stock is now in now trading above the volatile price range of $12.06 to $15.46 over the past one-month time frame.he stock witnessed five upward estimate revisions in the past 30 days. The Zacks Consensus Estimate also moved up over the same time frame, suggesting that more solid trading could be ahead for Celldex Therapeutics. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Celldex Therapeutics carries a Zacks Rank #2 (Buy).
Another stock in the med-biomed/gene industry worth considering is Achillion Pharmaceuticals, Inc. (ACHN - Snapshot Report), with a Zacks Rank #1 (Strong Buy).
I don't care about the past. Look to the future. If you were smart you'd buy shares or cover you short before you take a beating.
Not yet Frank. Up at children's hospital visiting my new twin grandsons. First things first Frank. Family then Cldx